financial results

Bionano also disclosed that it is expecting to report a nearly 18 percent jump in revenues for the third quarter.

The company's revenues were driven by its centralized and point-of-care solutions as well as its molecular diagnostics business, both rising in the single digits.

The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter.

Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.

The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.

The GenomeWeb Index, which now has 32 companies, lost 2.6 percent in September while the Dow Jones Industrial Average gained 2 percent over the same period.

The German diagnostics firm recently signed an agreement to be acquired by US-based OpGen in a transaction that is slated to close in early 2020.

The firm saw steady growth in its research reagents and screening businesses, and a 155 percent revenue increase in its bioproduction unit.

The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.